肿瘤细胞治疗研究
英文原题：Arming Vδ2 T Cells with Chimeric Antigen Receptors to Combat Cancer.
免疫治疗已成为肿瘤治疗领域一种有前景的方法，其中嵌合抗原受体（CAR）T 细胞治疗展现出显著的成功。
免疫疗法已成为癌症治疗中有前景的方法，嵌合抗原受体（CAR）T 细胞疗法取得显著成功。然而，肿瘤抗原异质性、免疫逃逸及 CAR-T 持久性有限等挑战，促使研究者探索其他细胞类型用于 CAR 策略。γδ T 细胞是具有固有肿瘤识别能力和多样免疫功能的独特淋巴细胞亚群，近年来受到越来越多关注。本综述提出，装备 Vγ9Vδ2 T 细胞可能成为开发下一代实体瘤免疫疗法的基础。在全面介绍 T 细胞生物学和创新 CAR 工程策略后，文章讨论 Vγ9Vδ2 CAR-T 克服实体瘤免疫疗法当前局限的临床潜力。尽管 Vγ9Vδ2 CAR-T 在癌症研究中的应用仍处于早期，且许多挑战尚待明确，但其代表癌症免疫治疗中有前景的突破。
Immunotherapy has emerged as a promising approach in the field of cancer treatment, with chimeric antigen receptor (CAR) T-cell therapy demonstrating remarkable success. However, challenges such as tumor antigen heterogeneity, immune evasion, and the limited persistence of CAR-T cells have prompted the exploration of alternative cell types for CAR-based strategies. Gamma delta T cells, a unique subset of lymphocytes with inherent tumor recognition capabilities and versatile immune functions, have garnered increasing attention in recent years. In this review, we present how arming V 2-T cells might be the basis for next-generation immunotherapies against solid tumors. Following a comprehensive overview of T-cell biology and innovative CAR engineering strategies, we discuss the clinical potential of V 2 CAR-T cells in overcoming the current limitations of immunotherapy in solid tumors. Although the applications of V 2 CAR-T cells in cancer research are relatively in their infancy and many challenges are yet to be identified, V 2 CAR-T cells represent a promising breakthrough in cancer immunotherapy.
MEMBER ACCOUNT
登录成功会直接打开下一页。
